Find all the latest information
acute myeloid leukemia
, arranged by types, translocations, and mutations.
Listed below are recently updated categories.
FDA clears IO-202, a novel LILRB4 antibody, for investigation as a new drug in AML
On May 29, 2020, the United States Food & Drug Administration (FDA) cleared IO-202, an antibody targeting leukocyte...
A step forward to implement leukemic stem cell assessment in the diagnostic workup of AML
Leukemic stem cells (LSCs) have been strongly associated with residual disease and relapse in patients with...
Pretransplant FLT3/ITD status as a prognostic marker for outcome in FLT3-mutated AML
Internal tandem duplication (ITD) of the juxtamembrane domain of the FMS-like tyrosine kinase-3 (FLT3/ITD) gene is...
EBMT ALWP recommendations for transplantation in patients with FLT3-ITD AML
The Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) recently...
Venetoclax in combination with hypomethylating agents for the treatment of older patients with NPM1-mutated acute myeloid leukemia
Approximately 30% of patients with acute myeloid leukemia (AML) have...
AACR 2020 | Preliminary phase I results of the AUGMENT-101 trial demonstrate clinical activity of SNDX-5613 in adults with relapsed/refractory acute leukemias
SNDX-5613 is a potent, highly selective,...
High immune checkpoint expression levels in patients with AML correlated with poor outcome
Immune checkpoint inhibitors (ICIs) in acute myeloid leukemia (AML) therapy are being evaluated in a variety...
AML World Awareness Day 2020 | The value of measurable residual disease in acute myeloid leukemia
Although up to 80% of patients with AML achieve morphologic complete remission (mCR) following...
Core binding factor
Epigenetic modifier mutations
Signaling pathway mutations
Transcription factor mutations
Tumor suppressor mutations